Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Cited by (250)

Items 101–200 of 250

1. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
   Bertrand, Florie, Montfort, Anne, Marcheteau, Elie, Imbert, Caroline, Gilhodes, Julia, Filleron, Thomas, Rochaix, Philippe, Andrieu-Abadie, Nathalie, Levade, Thierry, Meyer, Nicolas et al. · 2017 · Nature Communications
2. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
   Goswami, Sangeeta, Walle, Thomas, Cornish, Andrew E., Basu, Sreyashi, Anandhan, Swetha, Fernandez, Irina, Vence, Luis, Blando, Jorge, Zhao, Hao, Yadav, Shalini Singh et al. · 2020 · Nature Medicine
3. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
   de Filette, Jeroen, Andreescu, Corina, Cools, Filip, Bravenboer, Bert, Velkeniers, Brigitte · 2019 · Hormone and Metabolic Research
4. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
   Sato, Koichi, Akamatsu, Hiroaki, Murakami, Eriko, Sasaki, Seigo, Kanai, Kuninobu, Hayata, Atsushi, Tokudome, Nahomi, Akamatsu, Keiichiro, Koh, Yasuhiro, Ueda, Hiroki et al. · 2018 · Lung Cancer
5. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
   Teraoka, Shunsuke, Fujimoto, Daichi, Morimoto, Takeshi, Kawachi, Hayato, Ito, Munehiro, Sato, Yuki, Nagata, Kazuma, Nakagawa, Atsushi, Otsuka, Kojiro, Uehara, Keiichiro et al. · 2017 · Journal of Thoracic Oncology
6. The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
   Peng, Zhi, Cheng, Siyuan, Kou, Yan, Wang, Ziqi, Jin, Rong, Hu, Han, Zhang, Xiaotian, Gong, Ji-fang, Li, Jian, Lu, Ming et al. · 2020 · Cancer Immunology Research
7. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
   Hodi, F. Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris et al. · 2018 · Journal of Clinical Oncology
8. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
   Wu, Yi-Long, Lu, Shun, Cheng, Ying, Zhou, Caicun, Wang, Jie, Mok, Tony, Zhang, Li, Tu, Hai-Yan, Wu, Lin, Feng, Jifeng et al. · 2019 · Journal of Thoracic Oncology
9. Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
   Liu, Jingjing, Li, Shuang, Zhang, Shuang, Liu, Ying, Ma, Lixia, Zhu, Jing, Xin, Ying, Wang, Ying, Yang, Changliang, Cheng, Ying · 2019 · Journal of Clinical Laboratory Analysis
10. Exploring immunotherapy in colorectal cancer
    Weng, Junyong, Li, Shanbao, Zhu, Zhonglin, Liu, Qi, Zhang, Ruoxin, Yang, Yufei, Li, Xinxiang · 2022 · Journal of Hematology & Oncology
11. Tumour burden and efficacy of immune-checkpoint inhibitors
    Dall’Olio, Filippo G., Marabelle, Aurélien, Caramella, Caroline, Garcia, Camilo, Aldea, Mihaela, Chaput, Nathalie, Robert, Caroline, Besse, Benjamin · 2022 · Nature Reviews Clinical Oncology
12. Metal Drugs and the Anticancer Immune Response
    Englinger, Bernhard, Pirker, Christine, Heffeter, Petra, Terenzi, Alessio, Kowol, Christian R., Keppler, Bernhard K., Berger, Walter · 2019 · Chemical Reviews
13. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions
    Lee, Sang Hoon, Sung, Ji Yeon, Yong, Dongeun, Chun, Jongsik, Kim, Song Yee, Song, Joo Han, Chung, Kyung Soo, Kim, Eun Young, Jung, Ji Ye, Kang, Young Ae et al. · 2016 · Lung Cancer
14. Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
    Toi, Yukihiro, Sugawara, Shunichi, Sugisaka, Jun, Ono, Hirotaka, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Aso, Mari, Tsurumi, Kyoji et al. · 2019 · JAMA Oncology
15. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
    Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B. et al. · 2017 · Annals of Oncology
16. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
    Ricciuti, Biagio, Genova, Carlo, De Giglio, Andrea, Bassanelli, Maria, Dal Bello, Maria Giovanna, Metro, Giulio, Brambilla, Marta, Baglivo, Sara, Grossi, Francesco, Chiari, Rita · 2019 · Journal of Cancer Research and Clinical Oncology
17. Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
    Leonardi, Giulia C., Gainor, Justin F., Altan, Mehmet, Kravets, Sasha, Dahlberg, Suzanne E., Gedmintas, Lydia, Azimi, Roxana, Rizvi, Hira, Riess, Jonathan W., Hellmann, Matthew D. et al. · 2018 · Journal of Clinical Oncology
18. Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review
    Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S.E., Mazzeo, L., Provenzano, L., Kosta, S. et al. · 2024 · Annals of Oncology
19. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology & Therapeutics
20. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
    Garg, Abhishek D., Coulie, Pierre G., Van den Eynde, Benoit J., Agostinis, Patrizia · 2017 · Trends in Immunology
21. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
    Dalvin, Lauren A., Shields, Carol L., Orloff, Marlana, Sato, Takami, Shields, Jerry A. · 2018 · Retina
22. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i> -Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
    Jänne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crinò, Lucio, Orlov, Sergey, Blackhall, Fiona, Wolf, Juergen, Garrido, Pilar et al. · 2017 · JAMA
23. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
    Stroud, Chipman RG, Hegde, Aparna, Cherry, Cynthia, Naqash, Abdul R, Sharma, Nitika, Addepalli, Srikala, Cherukuri, Sulochana, Parent, Teresa, Hardin, Jessica, Walker, Paul · 2019 · Journal of Oncology Pharmacy Practice
24. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
    Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina et al. · 2019 · Cancer
25. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
    Ravi, Rajani, Noonan, Kimberly A., Pham, Vui, Bedi, Rishi, Zhavoronkov, Alex, Ozerov, Ivan V., Makarev, Eugene, V. Artemov, Artem, Wysocki, Piotr T., Mehra, Ranee et al. · 2018 · Nature Communications
26. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
    Hakozaki, Taiki, Richard, Corentin, Elkrief, Arielle, Hosomi, Yukio, Benlaïfaoui, Myriam, Mimpen, Iris, Terrisse, Safae, Derosa, Lisa, Zitvogel, Laurence, Routy, Bertrand et al. · 2020 · Cancer Immunology Research
27. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
    Danlos, François-Xavier, Voisin, Anne-Laure, Dyevre, Valérie, Michot, Jean-Marie, Routier, Emilie, Taillade, Laurent, Champiat, Stéphane, Aspeslagh, Sandrine, Haroche, Julien, Albiges, Laurence et al. · 2018 · European Journal of Cancer
28. The immune system and cancer evasion strategies: therapeutic concepts
    Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., Hoeller, S. · 2016 · Journal of Internal Medicine
29. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
    Saleh, Reem, Elkord, Eyad · 2020 · Seminars in Cancer Biology
30. EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
    Oshima, Yasuo, Tanimoto, Tetsuya, Yuji, Koichiro, Tojo, Arinobu · 2018 · JAMA Oncology
31. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
    Riera-Domingo, Carla, Audigé, Annette, Granja, Sara, Cheng, Wan-Chen, Ho, Ping-Chih, Baltazar, Fátima, Stockmann, Christian, Mazzone, Massimiliano · 2020 · Physiological Reviews
32. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
    Nishijima, Tomohiro F., Muss, Hyman B., Shachar, Shlomit S., Moschos, Stergios J. · 2016 · Cancer Treatment Reviews
33. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
    Toi, Yukihiro, Sugawara, Shunichi, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Tsurumi, Kyoji, Suzuki, Kana, Shimizu, Hisashi, Sugisaka, Jun et al. · 2018 · The Oncologist
34. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
    Chalabi, M., Cardona, A., Nagarkar, D.R., Dhawahir Scala, A., Gandara, D.R., Rittmeyer, A., Albert, M.L., Powles, T., Kok, M., Herrera, F.G. · 2020 · Annals of Oncology
35. Scientific Advances in Lung Cancer 2015
    Tsao, Anne S., Scagliotti, Giorgio V., Bunn, Paul A., Carbone, David P., Warren, Graham W., Bai, Chunxue, de Koning, Harry J., Yousaf-Khan, A. Uraujh, McWilliams, Annette, Tsao, Ming Sound et al. · 2016 · Journal of Thoracic Oncology
36. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    Karachaliou, Niki, Gonzalez-Cao, Maria, Crespo, Guillermo, Drozdowskyj, Ana, Aldeguer, Erika, Gimenez-Capitan, Ana, Teixido, Cristina, Molina-Vila, Miguel Angel, Viteri, Santiago, De Los Llanos Gil, Maria et al. · 2018 · Therapeutic Advances in Medical Oncology
37. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
    Kagamu, Hiroshi, Kitano, Shigehisa, Yamaguchi, Ou, Yoshimura, Kenichi, Horimoto, Katsuhisa, Kitazawa, Masashi, Fukui, Kazuhiko, Shiono, Ayako, Mouri, Atsuhito, Nishihara, Fuyumi et al. · 2020 · Cancer Immunology Research
38. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
    Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben et al. · 2019 · Cell
39. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
    Lee, Nayoung, Zakka, Labib R., Mihm, Martin C., Schatton, Tobias · 2016 · Pathology
40. The current state of molecular testing in the treatment of patients with solid tumors, 2019
    El‐Deiry, Wafik S., Goldberg, Richard M., Lenz, Heinz‐Josef, Shields, Anthony F., Gibney, Geoffrey T., Tan, Antoinette R., Brown, Jubilee, Eisenberg, Burton, Heath, Elisabeth I., Phuphanich, Surasak et al. · 2019 · CA: A Cancer Journal for Clinicians
41. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
    Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
42. Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
    Rogado, J., Sánchez-Torres, J.M., Romero-Laorden, N., Ballesteros, A.I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O. et al. · 2019 · European Journal of Cancer
43. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
    Lind, Hanne, Gameiro, Sofia R, Jochems, Caroline, Donahue, Renee N., Strauss, Julius, Gulley, James L, Palena, Claudia, Schlom, Jeffrey · 2020 · Journal for ImmunoTherapy of Cancer
44. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
    Disselhorst, Maria J, Quispel-Janssen, Josine, Lalezari, Ferry, Monkhorst, Kim, de Vries, Jeltje F, van der Noort, Vincent, Harms, Emmy, Burgers, Sjaak, Baas, Paul · 2019 · The Lancet Respiratory Medicine
45. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
    Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung · 2020 · Scientific Reports
46. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
    Yu, Man, Peng, Zhengxin, Qin, Min, Liu, Yang, Wang, Jingning, Zhang, Cai, Lin, Jiaming, Dong, Tianqi, Wang, Lulu, Li, Shasha et al. · 2021 · Molecular Cell
47. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
    Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., Routy, B. · 2019 · Annals of Oncology
48. Learning from clinical trials of neoadjuvant checkpoint blockade
    Versluis, Judith M., Long, Georgina V., Blank, Christian U. · 2020 · Nature Medicine
49. Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)
    Jeanson, Arnaud, Tomasini, Pascale, Souquet-Bressand, Maxime, Brandone, Nicolas, Boucekine, Mohamed, Grangeon, Mathieu, Chaleat, Solène, Khobta, Natalyia, Milia, Julie, Mhanna, Laurent et al. · 2019 · Journal of Thoracic Oncology
50. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
    Spigel, David R., Reynolds, Craig, Waterhouse, David, Garon, Edward B., Chandler, Jason, Babu, Sunil, Thurmes, Paul, Spira, Alexander, Jotte, Robert, Zhu, Jin et al. · 2018 · Journal of Thoracic Oncology
51. Metabolomic adaptations and correlates of survival to immune checkpoint blockade
    Li, Haoxin, Bullock, Kevin, Gurjao, Carino, Braun, David, Shukla, Sachet A., Bossé, Dominick, Lalani, Aly-Khan A., Gopal, Shuba, Jin, Chelsea, Horak, Christine et al. · 2019 · Nature Communications
52. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
    Subudhi, Sumit K., Aparicio, Ana, Gao, Jianjun, Zurita, Amado J., Araujo, John C., Logothetis, Christopher J., Tahir, Salahaldin A., Korivi, Brinda R., Slack, Rebecca S., Vence, Luis et al. · 2016 · Proceedings of the National Academy of Sciences
53. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
    Wang, Gui-Zhen, Zhang, Li, Zhao, Xin-Chun, Gao, San-Hui, Qu, Li-Wei, Yu, Hong, Fang, Wen-Feng, Zhou, Yong-Chun, Liang, Fan, Zhang, Chen et al. · 2019 · Nature Communications
54. Efficacy of PD-1 &amp; PD-L1 inhibitors in older adults: a meta-analysis
    Elias, Rawad, Giobbie-Hurder, Anita, McCleary, Nadine Jackson, Ott, Patrick, Hodi, F. Stephen, Rahma, Osama · 2018 · Journal for ImmunoTherapy of Cancer
55. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
    Fucà, Giovanni, Galli, Giulia, Poggi, Marta, Lo Russo, Giuseppe, Proto, Claudia, Imbimbo, Martina, Ferrara, Roberto, Zilembo, Nicoletta, Ganzinelli, Monica, Sica, Antonio et al. · 2019 · ESMO Open
56. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
    Abu-Sbeih, Hamzah, Ali, Faisal S., Alsaadi, Dana, Jennings, Joseph, Luo, Wenyi, Gong, Zimu, Richards, David M., Charabaty, Aline, Wang, Yinghong · 2018 · Journal for ImmunoTherapy of Cancer
57. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
    Sebastian, Martin, Schröder, Andreas, Scheel, Birgit, Hong, Henoch S., Muth, Anke, von Boehmer, Lotta, Zippelius, Alfred, Mayer, Frank, Reck, Martin, Atanackovic, Djordje et al. · 2019 · Cancer Immunology, Immunotherapy
58. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
    Kobayashi, Tomoko, Iwama, Shintaro, Yasuda, Yoshinori, Okada, Norio, Tsunekawa, Taku, Onoue, Takeshi, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki et al. · 2018 · Journal of the Endocrine Society
59. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
    Koelzer, Viktor H., Rothschild, Sacha I., Zihler, Deborah, Wicki, Andreas, Willi, Berenika, Willi, Niels, Voegeli, Michèle, Cathomas, Gieri, Zippelius, Alfred, Mertz, Kirsten D. · 2016 · Journal for ImmunoTherapy of Cancer
60. Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC
    Kaira, Kyoichi, Higuchi, Tetsuya, Naruse, Ichiro, Arisaka, Yukiko, Tokue, Azusa, Altan, Bolag, Suda, Satoshi, Mogi, Akira, Shimizu, Kimihiro, Sunaga, Noriaki et al. · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
61. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
    Knudson, Karin M., Hicks, Kristin C., Luo, Xiaoling, Chen, Jin-Qiu, Schlom, Jeffrey, Gameiro, Sofia R. · 2018 · OncoImmunology
62. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
    Hendry, Shona A., Farnsworth, Rae H., Solomon, Benjamin, Achen, Marc G., Stacker, Steven A., Fox, Stephen B. · 2016 · Frontiers in Immunology
63. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues
    Majzner, Robbie G., Simon, Jason S., Grosso, Joseph F., Martinez, Daniel, Pawel, Bruce R., Santi, Mariarita, Merchant, Melinda S., Geoerger, Birgit, Hezam, Imene, Marty, Virginie et al. · 2017 · Cancer
64. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
    Fizazi, Karim, Drake, Charles G., Beer, Tomasz M., Kwon, Eugene D., Scher, Howard I., Gerritsen, Winald R., Bossi, Alberto, den Eertwegh, Alfons J.M. van, Krainer, Michael, Houede, Nadine et al. · 2020 · European Urology
65. RAS: Striking at the Core of the Oncogenic Circuitry
    Gimple, Ryan C., Wang, Xiuxing · 2019 · Frontiers in Oncology
66. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Qiao, Meng, Jiang, Tao, Liu, Xinyu, Mao, Shiqi, Zhou, Fei, Li, Xuefei, Zhao, Chao, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang et al. · 2021 · Journal of Thoracic Oncology
67. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
    Suresh, Karthik, Psoter, Kevin J., Voong, Khinh Ranh, Shankar, Bairavi, Forde, Patrick M., Ettinger, David S., Marrone, Kristen A., Kelly, Ronan J., Hann, Christine L., Levy, Benjamin et al. · 2019 · Journal of Thoracic Oncology
68. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
    Fumet, Jean-David, Richard, Corentin, Ledys, Fanny, Klopfenstein, Quentin, Joubert, Philippe, Routy, Bertrand, Truntzer, Caroline, Gagné, Andréanne, Hamel, Marc-André, Guimaraes, Camila Figueiredo et al. · 2018 · British Journal of Cancer
69. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
    David, Justin M., Dominguez, Charli, McCampbell, Kristen K., Gulley, James L., Schlom, Jeffrey, Palena, Claudia · 2017 · OncoImmunology
70. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
    Park, Hyo Jung, Kim, Kyung Won, Pyo, Junhee, Suh, Chong Hyun, Yoon, Shinkyo, Hatabu, Hiroto, Nishino, Mizuki · 2020 · Radiology
71. The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
    Briere, David M., Li, Shuai, Calinisan, Andrew, Sudhakar, Niranjan, Aranda, Ruth, Hargis, Lauren, Peng, David H., Deng, Jiehui, Engstrom, Lars D., Hallin, Jill et al. · 2021 · Molecular Cancer Therapeutics
72. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
    Yamauchi, Ichiro, Sakane, Yoriko, Fukuda, Yorihide, Fujii, Toshihito, Taura, Daisuke, Hirata, Masakazu, Hirota, Keisho, Ueda, Yohei, Kanai, Yugo, Yamashita, Yui et al. · 2017 · Thyroid
73. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
    Moon, Edmund K., Wang, Liang-Chuan S., Bekdache, Kheng, Lynn, Rachel C., Lo, Albert, Thorne, Stephen H., Albelda, Steven M. · 2018 · OncoImmunology
74. Iron induces anti-tumor activity in tumor-associated macrophages
    Costa da Silva, Milene, Breckwoldt, Michael O., Vinchi, Francesca, Correia, Margareta P., Stojanovic, Ana, Thielmann, Carl Maximilian, Meister, Michael, Muley, Thomas, Warth, Arne, Platten, Michael et al. · 2017 · Frontiers in Immunology
75. Racial and ethnic disparities in hematologic malignancies
    Kirtane, Kedar, Lee, Stephanie J. · 2017 · Blood
76. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
    Zhao, Sha, Gao, Guanghui, Li, Wei, Li, Xuefei, Zhao, Chao, Jiang, Tao, Jia, Yijun, He, Yayi, Li, Aiwu, Su, Chunxia et al. · 2019 · Lung Cancer
77. EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
    Jia, Yijun, Li, Xuefei, Jiang, Tao, Zhao, Sha, Zhao, Chao, Zhang, Limin, Liu, Xiaozhen, Shi, Jinpeng, Qiao, Meng, Luo, Jiawei et al. · 2019 · International Journal of Cancer
78. Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
    Chen, Bin, Garmire, Lana, Calvisi, Diego F., Chua, Mei-Sze, Kelley, Robin K., Chen, Xin · 2020 · Nature Reviews Gastroenterology &amp; Hepatology
79. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
    Dy, Grace K., Govindan, Ramaswamy, Velcheti, Vamsidhar, Falchook, Gerald S., Italiano, Antoine, Wolf, Jürgen, Sacher, Adrian G., Takahashi, Toshiaki, Ramalingam, Suresh S., Dooms, Christophe et al. · 2023 · Journal of Clinical Oncology
80. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
    Ferrara, Roberto, Mezquita, Laura, Auclin, Edouard, Chaput, Nathalie, Besse, Benjamin · 2017 · Cancer Treatment Reviews
81. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
    Sceneay, Jaclyn, Goreczny, Gregory J., Wilson, Kristin, Morrow, Sara, DeCristo, Molly J., Ubellacker, Jessalyn M., Qin, Yuanbo, Laszewski, Tyler, Stover, Daniel G., Barrera, Victor et al. · 2019 · Cancer Discovery
82. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
    Kimbara, Shiro, Fujiwara, Yutaka, Iwama, Shintaro, Ohashi, Ken, Kuchiba, Aya, Arima, Hiroshi, Yamazaki, Naoya, Kitano, Shigehisa, Yamamoto, Noboru, Ohe, Yuichiro · 2018 · Cancer Science
83. Targeting the interleukin-17 immune axis for cancer immunotherapy
    Vitiello, Gerardo A., Miller, George · 2020 · Journal of Experimental Medicine
84. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
    Pai, Chien-Chun Steven, Huang, John T., Lu, Xiaoqing, Simons, Donald M., Park, Chanhyuk, Chang, Anthony, Tamaki, Whitney, Liu, Eric, Roybal, Kole T., Seagal, Jane et al. · 2019 · Immunity
85. Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC
    Rakaee, Mehrdad, Adib, Elio, Ricciuti, Biagio, Sholl, Lynette M., Shi, Weiwei, Alessi, Joao V., Cortellini, Alessio, Fulgenzi, Claudia A. M., Viola, Patrizia, Pinato, David J. et al. · 2023 · JAMA Oncology
86. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli, Andrea, Cerbelli, Bruna, Lionetto, Luana, Zizzari, Ilaria, Salati, Massimiliano, Pisano, Annalinda, Federica, Mazzuca, Simmaco, Maurizio, Nuti, Marianna, Marchetti, Paolo · 2018 · Journal of Translational Medicine
87. Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images
    Sha, Lingdao, Osinski, Boleslaw L., Ho, Irvin Y., Tan, Timothy L., Willis, Caleb, Weiss, Hannah, Beaubier, Nike, Mahon, Brett M., Taxter, Tim J., Yip, Stephen S. F · 2019 · Journal of Pathology Informatics
88. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
    Kim, Hye In, Kim, Mijin, Lee, Se-Hoon, Park, So Young, Kim, Young Nam, Kim, Hosu, Jeon, Min Ji, Kim, Tae Yong, Kim, Sun Wook, Kim, Won Bae et al. · 2018 · OncoImmunology
89. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
    Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J. · 2017 · Oncotarget
90. Clinical pharmacology considerations for the development of immune checkpoint inhibitors
    Sheng, Jennifer, Srivastava, Shivani, Sanghavi, Kinjal, Lu, Zheng, Schmidt, Brian J., Bello, Akintunde, Gupta, Manish · 2017 · The Journal of Clinical Pharmacology
91. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
    Friedlaender, Alex, Drilon, Alexander, Weiss, Glen J., Banna, Giuseppe L., Addeo, Alfredo · 2020 · Cancer Treatment Reviews
92. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme
    Grossi, Francesco, Crinò, Lucio, Logroscino, Antonio, Canova, Stefania, Delmonte, Angelo, Melotti, Barbara, Proto, Claudia, Gelibter, Alain, Cappuzzo, Federico, Turci, Daniele et al. · 2018 · European Journal of Cancer
93. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
    Scheel, Andreas H., Ansén, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael et al. · 2016 · OncoImmunology
94. Targeting EGFR in Lung Cancer: Current Standards and Developments
    Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis · 2018 · Drugs
95. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A. · 2016 · Lung Cancer
96. A CT-based Radiomics Signature is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
    Ligero, Marta, Garcia-Ruiz, Alonso, Viaplana, Cristina, Villacampa, Guillermo, Raciti, Maria V., Landa, Jaid, Matos, Ignacio, Martin-Liberal, Juan, Ochoa-de-Olza, Maria, Hierro, Cinta et al. · 2021 · Radiology
97. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer
    Chen, Dawei, Barsoumian, Hampartsoum B., Yang, Liangpeng, Younes, Ahmed I., Verma, Vivek, Hu, Yun, Menon, Hari, Wasley, Mark, Masropour, Fatemeh, Mosaffa, Sara et al. · 2020 · Cancer Immunology Research
98. FDA analyses of survival in older adults with metastatic non–small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies
    Marur, Shanthi, Singh, Harpreet, Mishra-Kalyani, Pallavi, Larkins, Erin, Keegan, Patricia, Sridhara, Rajeshwari, Blumenthal, Gideon M., Pazdur, Richard · 2018 · Seminars in Oncology
99. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer
    Iwatate, Yosuke, Hoshino, Isamu, Yokota, Hajime, Ishige, Fumitaka, Itami, Makiko, Mori, Yasukuni, Chiba, Satoshi, Arimitsu, Hidehito, Yanagibashi, Hiroo, Nagase, Hiroki et al. · 2020 · British Journal of Cancer
100. Clinical impact of probiotics on the efficacy of <scp>anti‐PD</scp>‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
     Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya‐Kawano, Yuko, Otsubo, Kohei et al. · 2021 · International Journal of Cancer